Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the ...
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient ...
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma ...
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx Pharmaceutical entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. Ultragenyx received the voucher upon FDAs ...
At ESC Congress 2026, incretin-based therapies, including GLP-1 receptor agonists, featured across heart failure (HF), chronic kidney disease (CKD), atrial fibrillation (AF), obesity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results